Jianmin Group announced that the company received the “Drug Registration Certificate” approved and issued by the State Drug Administration, and the developed Claribolol ointment was approved for marketing. This drug is a class 4 chemical drug with a specification of 2%. It is a prescription drug. The indication is topical topical treatment for patients with mild to moderate atopic dermatitis aged 3 months and above. As of August 31, 2026, the drug had invested a total of about 11.2741 million yuan in research and development costs. This approval will enrich the company's product line. It is expected that it will not have a significant impact on the company's performance in the short term, and there is uncertainty about its market share after listing.

Jianmin Group announced that the company received the “Drug Registration Certificate” approved and issued by the State Drug Administration, and the developed Claribolol ointment was approved for marketing. This drug is a class 4 chemical drug with a specification of 2%. It is a prescription drug. The indication is topical topical treatment for patients with mild to moderate atopic dermatitis aged 3 months and above. As of August 31, 2026, the drug had invested a total of about 11.2741 million yuan in research and development costs. This approval will enrich the company's product line. It is expected that it will not have a significant impact on the company's performance in the short term, and there is uncertainty about its market share after listing.